ProPhase Labs, Inc. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
ProPhase Labs, Inc. (PRPH) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of -$0.01 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2019-03-26
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2018-09-30 was -$0.01.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-09-30 was -$0.02, a 133.33% decline year-over-year.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-06-30 was -$0.08, a 900.00% decline year-over-year.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-03-31 was $2.61.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2018 was -$0.01, a 100.36% decline from fiscal 2017.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2017 was $2.75, a 3828.57% increase from fiscal 2016.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2016 was $0.07.
- ProPhase Labs, Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2015 was -$0.09.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month as first filed | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month as first filed | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month as first filed | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$0.01 10-K · filed 2019-03-26 | |||||||
| 2018-09-30 | -$0.01 10-Q · filed 2018-11-14 | -$0.01 10-Q · filed 2018-11-14 | ||||||
| 2017-12-31 | $2.75 10-K · filed 2019-03-26 | $1.77 10-K · filed 2018-03-28 | ||||||
| 2017-09-30 | -$0.02 10-Q · filed 2018-11-14 | $2.58 10-Q · filed 2018-11-14 | $1.61 10-Q · filed 2017-11-13 | |||||
| 2017-06-30 | -$0.08 10-Q/A · filed 2018-08-20 | -$0.05 10-Q · filed 2017-08-11 | $2.54 10-Q/A · filed 2018-08-20 | $1.58 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | $2.61 10-Q/A · filed 2018-08-20 | $1.62 10-Q · filed 2017-05-15 | ||||||
| 2016-12-31 | $0.07 10-K/A · filed 2018-08-20 | |||||||
| 2016-09-30 | $0.06 10-Q/A · filed 2018-08-20 | $0.07 10-Q/A · filed 2018-08-20 | ||||||
| 2016-06-30 | $0.01 10-Q/A · filed 2018-08-20 | $0.01 10-Q/A · filed 2018-08-20 | ||||||
| 2015-12-31 | -$0.09 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |